Company news
Theriva Biologics, Inc. news in 2026
Theriva Biologics, Inc.'s news releases, calls and decks from 2026, newest first.
Theriva™ Biologics Announces Reverse Stock Split
November 20, 2026
Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results
November 12, 2026
Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.
November 2, 2026
Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
August 12, 2026
Theriva Biologics: Q2 Earnings Snapshot
August 11, 2026
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
August 11, 2026
Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
August 7, 2026
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
August 6, 2026
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
July 7, 2026
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
May 5, 2026
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
April 17, 2026
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
March 23, 2026
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
March 12, 2026
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
February 18, 2026
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
February 3, 2026
Decks in 2026
- Investor Presentation (May 2026)
Investor deck · 53 slides · May 2026
- Investor Presentation (January 2026)
Investor deck · 54 slides · January 2026